CD274 and neoplasm: The ASCO recommends that patients with recurrent or metastatic HNSCC undergo PD-L1 immunohistochemistry testing (evidence quality high, strong recommendation) and that tumor mutational burden (TMB) testing should be performed when immunohistochemistry is not available or if the patient has a rare tumor type (evidence quality high, strong recommendation).